财中社1月20日电康诺亚-B(02162)发布公告,与Prolium就CM355(ICP-B02)的开发及商业化订立许可协议。根据协议,Prolium将拥有在全球非肿瘤适应症及亚洲以外地区肿瘤适应症方面开发、注册、生产及商业化CM355的独家权利。相关付款将由公司及北京诺诚健华平均分摊。
CM355是一种CD20×CD3双特异性抗体,目前正在进行临床试验,评估其在治疗复发/难治性非霍奇金淋巴瘤患者时的安全性及疗效。根据协议,成都康诺亚及北京诺诚健华将共同有权收取金额为1750万美元的首付款和近期付款,最高可达5.03亿美元的额外付款,具体金额取决于若干商业、临床开发及监管里程碑的达成。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.